RIL, Paytm, Axis Bank, Sun Pharma among buzzing stocks as NIFTY50, SENSEX gain nearly 1%

The Indian benchmark indices, SENSEX and NIFTY50, were trading in the green during the afternoon session on Monday, April 27, bolstered by gains in pharma and media stocks and positive cues in global markets despite the breakdown of peace talks between Iran and the United States.

Investor sentiment also improved as the three-day trade negotiations between India and the US concluded, with both countries agreeing to maintain momentum and continue talks.

The SENSEX and NIFTY 50 both rallied as much as 0.88% to hit their intraday highs of 77,341.53 and 24,107.60, respectively, during the opening bell.

While both indices were off their day’s highs, they continued trading in the positive territory at around 12:40 PM. The S&P BSE SENSEX soared by 588.37 points, or 0.77%, to 77,252.58. Meanwhile, NSE’s NIFTY50 stood at 24,078.75, marking a 180.80 points, or 0.76% increase.

On Friday, the foreign institutional investors (FIIs) sold shares worth ₹8,827.87 crore, while the domestic institutional investors (DIIs) purchased equities worth ₹4,700.71 crore on a net basis, according to exchange data.

The NIFTY50 index was supported by gains in Sun Pharma (6.96%), JSW Steel (2.71%), Adani Ports (2.50%), TCS (2.19%) and SBI Life Insurance Company (2.16%), which were among the top winners.

On the contrary, the top losers included Shriram Finance (-4%), Axis Bank (-3.51%), BEL (-1.79%), Coal India (-0.79%) and Tata Consumer Products (-0.60%).

Buzzing stocks on April 27: Check list

Shares of the oil-to-telecom conglomerate Reliance Industries (RIL) rose as much as 1.31% to hit an intraday high of ₹1,345.20 apiece on the National Stock Exchange (NSE) on Monday, April 27, following its result announcement on Friday.

However, during the pre-market opening session on NSE, RIL shares were down around 2% to ₹1,300 after investors reacted to subdued Q4 earnings and the impact of the West Asia crisis on the company's profits.

The company recorded a 13% YoY fall in net profits. The revenue from core operations witnessed a 13% rise in the January to March quarter to ₹2.98 lakh crore, compared to ₹2.65 lakh crore in the same period a year ago.

The stock of Cohance Lifesciences hit its 20% upper limit at ₹432.10 per unit on the NSE, after it announced the appointment of the former Cipla CEO, Umang Vohra, as its Executive Chairman, effective May 1, 2026, and Group CEO, effective May 20, 2026.

“Mr. Vohra succeeds Mr. Vivek Sharma, who steps down as Executive Chairman for personal reasons. Mr Sharma will continue to be with Cohance as an Advisor for the next 9 months and will support a smooth transition,” the company said in a press release.

Axis Bank shares fell nearly 5% to touch an intraday low of ₹1,299.90 per unit in early morning trades on the NSE on Monday, April 27, reacting to its Q4FY26 earnings.

The private lender reported flat growth in Q4 net profit to ₹7,071 crore, down 0.6% YoY, mainly due to a sharp spike in provisions and a trading loss. Total provisions and contingencies rose 159% YoY to ₹3,522 crore during the quarter.

Its net interest income advanced 4.7% YoY to ₹14,457 crore compared to ₹13,811 crore in the year-ago period, while net interest margins (NIM) stood at 3.62%. Asset quality improved, with gross NPAs declining to 1.23% (down 17bps QoQ) and net NPAs to 0.37% (down 5bps QoQ). Slippages moderated sharply, and credit costs improved sequentially.

Axis Bank advances saw a rise of 19% YoY and 6% QoQ to ₹12.34 lakh crore, led by strong growth in corporate and SME segments. Along with the results, Axis Bank also announced a final dividend of ₹1 per share for its shareholders.

IndusInd Bank stock jumped 6.13% to hit the session’s peak of ₹899.9 per equity share, after the private lender swung back to profitability with net profit of ₹594 crore compared to a loss of ₹2,236 crore in the year-ago period due to lower provisions, which fell sharply by 38.6% YoY to ₹1,484 crore during the quarter.

IndusInd Bank's net interest income (NII) increased 43.4% YoY to ₹4,372 crore, driven by a low base and improved interest income dynamics. Net interest margin (NIM) improved to 3.39% from 2.25% a year ago.

Shares of Sun Pharma jumped as much as 9.94% to an intraday high of ₹1,766.90 apiece, as it announced its plans to acquire US-based healthcare firm, Organon & Co., at an enterprise value of $11.75 billion, according to an exchange filing.

The NSE filing showed that Sun Pharmaceutical’s deal to acquire Organon & Co. will be an all‑cash transaction for $14.00 per share for all outstanding shares of the New Jersey-based company.

“Sun Pharmaceutical Industries Limited and Organon & Co. today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all‑cash transaction with an enterprise valuation of $11.75 billion,” the company informed the stock exchange.

The stock of One 97 Communications, the parent company of Paytm, declined as much as 8.39% to touch the day’s low of ₹1,051.10 per equity share, following the Reserve Bank of India's (RBI) action on Paytm Payments Bank (PPBL).

The apex bank on Friday announced the cancellation of the banking licence issued to Paytm Payments Bank for non-compliance with norms, saying the affairs of the bank were conducted in a manner detrimental to the interest of its depositors.

However, the company on Friday said the Reserve Bank of India's (RBI) action on Paytm Payments Bank Ltd (PPBL) has no financial or business impact on the company, reiterating that it does not have any material business arrangements or exposure with the banking entity.

Shares of Mahindra & Mahindra Financial Services advanced as much as 9.28% to an intraday high of ₹331 per unit, as it clocked a standalone net profit of ₹872.98 crore in Q4 FY26, up 55.02% YoY from ₹563.14 crore in the year-ago period.

Furthermore, its board of directors recommends a final dividend of ₹7.50 per equity share of face value of ₹2 each (i.e., 375%) for the financial year ended 31st March 2026.

"The dividend on equity shares for the year ended 31st March 2026, as recommended by the Board of Directors and if approved at the Annual General Meeting scheduled on Tuesday, 21 st July 2026, will be paid by the Company, through permitted modes, after Tuesday, 21st July 2026, to eligible shareholders," it stated.

Shares of The India Cements Ltd (ICL) skyrocketed as much as 15.26% to the day’s peak of ₹469.90 per unit on Monday, after the company released its latest set of numbers for the January-March quarter of the financial year 2025-26.

On April 25, it posted a more than fourfold jump in consolidated profit after tax to ₹59.5 crore for Q4 FY26 due to an increase in volume and sales realisation.

India Cement, a subsidiary of Aditya Birla group firm UltraTech Cement, had reported a net profit of ₹14.67 crore in the March quarter of FY25, helped by asset sales, according to a BSE filing.

Its revenue from operations climbed 2.6% to ₹1,228.65 crore in the latest March quarter of the fiscal year 2026, compared to ₹1,197.57 crore a year back. Total expenses stood at ₹1,174.79 crore, down 10.5% year-on-year.